Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Nivolumab in Advanced Gastric and Esophageal Cancer (OASIS)
NCT04503967Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of anlotinib, nivolumab in gastric adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
anlotinibnivolumab
03
Conditions
gastric adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04503967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503967.